Perspective Therapeutics, Inc. · AMEX:CATX

Perspective Therapeutics — Investor Presentation (May 2025)

26 slides from Perspective Therapeutics's investor presentation, May 30, 2025

1. Slide 1: Investor Call ASCO 2025 Presentation

   Investor Call ASCO 2025 Presentation

2. Slide 2: Legal Disclaimers

   Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s

3. Slide 3: Developing the Next Generation of Targeted Therapies

   Developing the Next Generation of Targeted Therapies

4. Slide 4: Broad Proprietary Pipeline

   Broad Proprietary Pipeline Three lead programs in clinic with multiple programs in preclinical development Program . (ERE Target Disease VMT01/02 Melanoma (mciR) (MC1R Imaging & Therapy) Neuroendocrine Tumors VMT-a-NET (ssTR2) Other SSTR2 Expressing Tumors Psv359 a a ia aa Prostate XX (PSMA) (PSMA I

5. Slide 5: Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment

   Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT

6. Slide 6: Neuroendocrine Tumors: VMT-α-NET

   Neuroendocrine Tumors: VMT-⍺-NET

7. Slide 7: Neuroendocrine Tumors: VMT-α-NET

   Neuroendocrine Tumors: VMT-a-NET Targeting the somatostatin receptor to treat neuroendocrine and other cancers Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances Disease Most neuroendocrine tumors highly express somatostatin receptor type 2 (SSTR2) Overvi

8. Slide 8: NETs Trials

   NETs Trials Lu-DOTA’ Lu-EDOTREOTIDE ‘Pb-DC (Ph 3 dose is fixed 10.2 MBq) ©28.4ys8.Smonths? | NE(95% I-12 months, NE) 13% (195/125) vs. 4% (0%/4%) 29.496 confirmed 41.2% (6%/35%) w/ unconfirmed +USPI; “DOI: 10.1056/NEJMoa1607427; "NANETS 2021; “DOI: 10.1016/S0140-6736124)00701-3; “ENETS 2025: * 7aSCO

9. Slide 9: Interim safety and efficacy data of [212Pb]VMT-α-NET in SSTR2 expressing NETs

   Interim safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)

10. Slide 10: Key Takeaway Points/Conclusions

    Key Takeaway Points/Conclusions

11. Slide 11: Trial Design: [212Pb]VMT-α-NET Phase 1/2a For Neuroendocrine Tumors

    Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

12. Slide 12: Patient Disposition

    Patient Disposition Cohort 1 (2.5 mCi) Received at least 1 treatment n=2 Completed 4 treatments n=2 Received 21 scan after 4 treatments n=2 Cohort 2 (5.0 mCi) Received at least 1 treatment n=7 Completed 4 treatments n=6* Received 21 scan after 4 treatments n=6 Additional Cohort 2 Received at least 1

13. Slide 13: Baseline Patient Characteristics

    Baseline Patient Characteristics

14. Slide 14: [212Pb]VMT-α-NET Was Well Tolerated

    [212Pb]VMT-α-NET Was Well Tolerated

15. Slide 15: Seven Patients Experienced Grade Blood Creatinine Increase

    Seven Patients Experienced Grade 1 Blood Creatinine Increase

16. Slide 16: Mild and Generally Transient Blood Creatinine Increase

    Mild and Generally Transient Blood Creatinine Increase

17. Slide 17: ASCO-GI 2025: Anti-Tumor Activity

    ASCO-GI 2025: Anti-Tumor Activity

18. Slide 18: Update at ASCO: Anti-Tumor Activity

    Update at ASCO: Anti-Tumor Activity

19. Slide 19: ASCO-GI 2025: Eight of Nine Patients Remain on Study

    ASCO-GI 2025: Eight of Nine Patients Remain on Study

20. Slide 20: Updated at ASCO 2025: Seven of Nine Patients Remain on Study

    Updated at ASCO 2025: Seven of Nine Patients Remain on Study

21. Slide 21: ASCO-GI 2025: Signal of Sustained Anti-Tumor Activity

    ASCO-GI 2025: Signal of Sustained Anti-Tumor Activity

22. Slide 22: Updated at ASCO 2025: Signal of Sustained Anti-Tumor Activity

    Updated at ASCO 2025: Signal of Sustained Anti-Tumor Activity

23. Slide 23: Patient (103-105) with Confirmed PR After [212Pb]VMT-α-NET

    Patient (103-105) with Confirmed PR After [212Pb]VMT-α-NET

24. Slide 24: Next steps and concluding remarks

    Next steps and concluding remarks

25. Slide 25: Conclusion & Next Steps

    Conclusion & Next Steps [?Pb]VMT-a-NET was well tolerated, supporting rationale for potential dose escalation [222Pb] VMT-a-NET was well-tolerated? * No DLTs, no grade 4 or grade 5 AEs or deaths; 10 out of 42 (24%) patients experienced a Grade 3 TEAE * No discontinuations due to AE have occurred * N

26. Slide 26: Q & A

    Q & A

Perspective Therapeutics — Investor Presentation (May 2025) on 6ix